Stryker Corporation $SYK Shares Acquired by Czech National Bank

Key Points

• Czech National Bank increased its stake in Stryker Corporation by 6.6%, acquiring an additional 5,195 shares, bringing their total ownership to 84,073 shares valued at approximately $33.3 million.
• Director Ronda E. Stryker sold 200,000 shares at an average price of $376.45, resulting in a 5.84% decrease in her holdings, which now total about $1.21 billion.
• Stryker reported earnings per share (EPS) of $3.13 for the last quarter, exceeding analyst expectations, and announced a quarterly dividend of $0.84, payable on October 31st.

Czech National Bank grew its position in Stryker Corporation (NYSE:SYK - Free Report) by 6.6% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 84,073 shares of the medical technology company's stock after acquiring an additional 5,195 shares during the period. Czech National Bank's holdings in Stryker were worth $33,262,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Capital A Wealth Management LLC purchased a new stake in shares of Stryker during the fourth quarter worth about $26,000. Goodman Advisory Group LLC purchased a new stake in Stryker during the 1st quarter valued at about $32,000. City Holding Co. grew its stake in Stryker by 528.6% during the 1st quarter. City Holding Co. now owns 88 shares of the medical technology company's stock valued at $33,000 after acquiring an additional 74 shares in the last quarter. Ransom Advisory Ltd purchased a new stake in Stryker during the 1st quarter valued at about $37,000. Finally, Smallwood Wealth Investment Management LLC purchased a new stake in Stryker during the 1st quarter valued at about $40,000. Institutional investors and hedge funds own 77.09% of the company's stock.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total value of $75,290,000.00. Following the sale, the director directly owned 3,222,108 shares of the company's stock, valued at approximately $1,212,962,556.60. This represents a 5.84% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Viju Menon sold 500 shares of the stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the sale, the insider directly owned 12,511 shares in the company, valued at approximately $4,886,921.71. This represents a 3.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 5.20% of the company's stock.

Stryker Price Performance

Stryker stock opened at $377.49 on Tuesday. The firm has a market cap of $144.32 billion, a PE ratio of 50.00, a price-to-earnings-growth ratio of 2.76 and a beta of 0.93. Stryker Corporation has a 52-week low of $329.16 and a 52-week high of $406.19. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. The company's 50 day moving average is $388.68 and its two-hundred day moving average is $379.44.

Stryker (NYSE:SYK - Get Free Report) last released its earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.07 by $0.06. The company had revenue of $6.02 billion for the quarter, compared to analyst estimates of $5.92 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The firm's quarterly revenue was up 11.1% on a year-over-year basis. During the same period in the prior year, the business earned $2.81 EPS. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, research analysts expect that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be given a $0.84 dividend. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. Stryker's dividend payout ratio is currently 44.50%.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Wall Street Zen raised shares of Stryker from a "hold" rating to a "buy" rating in a research note on Friday, July 18th. Evercore ISI boosted their target price on shares of Stryker from $390.00 to $415.00 and gave the company an "outperform" rating in a report on Tuesday, July 8th. Wells Fargo & Company boosted their target price on shares of Stryker from $435.00 to $445.00 and gave the company an "overweight" rating in a report on Friday, August 1st. BTIG Research reiterated a "buy" rating on shares of Stryker in a report on Monday, July 14th. Finally, Truist Financial set a $415.00 target price on shares of Stryker and gave the company a "hold" rating in a report on Monday, August 4th. Fourteen analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $431.42.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.